Clinical Trials Browser

Terminated × Erlotinib Hydrochloride × Head & Neck × Clear all

NCT00448240 2025-03-18

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Phase 2/3 Terminated

6 enrolled 4 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01192815 2020-05-12

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Phase 2 Terminated

2 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT00750555 2019-02-26

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Phase 2 Terminated

Head and Neck Neoplasms

NCT00573989 2019-01-03

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Phase 1/2 Terminated

27 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00392665 2017-04-13

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Terminated

36 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

NCT00412217 2016-11-25

A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer

Phase 3 Terminated

94 enrolled 6 charts

Head and Neck Neoplasms